Cargando...
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
PURPOSE: To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies, including the effect of these treatments on sex hormone levels, any reported...
Guardado en:
| Publicado en: | Breast Cancer Res Treat |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6773272/ https://ncbi.nlm.nih.gov/pubmed/30467659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4996-3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|